Introduction

Pharmaceutical Toxicology in Practice: A Guide for Non-Clinical Development

Volumn , Issue , 2011, Pages 1-7

  Lodola, Alberto ^a   Stadler, Jeanne ^b  

^a ToxAdvantage ^*  (France)

^b EURL Jeanne STADLER   (France)

Author keywords

"omics" technologies, biomarkers of toxicity nonclinical toxicity of drug development candidates; Modern "postindustrial" era of toxicology pharmaceutical and nonclinical toxicology; REACH risk management process environmental risk management plan preparation

Indexed keywords

EID: 84885981693     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470909911.ch1     Document Type: Editorial

References (28)

1. Merriam-Webster's On-Line Dictionary, 2009. http://www.merriam-webster.com/
2. Cambridge Advanced Learner's Dictionary, 2009. http://dictionary.cambridge.org/
3. Gilbert SG and Hayes A, 2005. Milestones of Toxicology. http://toxipedia.org/display/ toxipedia/Milestones+of+Toxicology
4. Anon, 2009. Vioxx News at http://www.vioxxnews.com/
5. Europe, the Middle East, and Africa, EMEA, 2002. Note for guidance on phototoxicity testing. http://www.emea.europa.eu/pdfs/human/swp/039801en.pdf
6. Hon GC, and Hawkins RD, Ren B, 2009. Predictive chromatin signatures in the mammalian genome. Hum Mol Genet 18:R195-R201
7. Morozova O, Hirst M and Marra MA, 2009. Applications of new sequencing technologies for transcriptome analysis. Annu Rev Genomics Hum Genet 10:135-151
8. Wu X and Xiao H, 2009. Progress in the detection of human genome structural variations. Sci China C Life Sci 52:560-567
9. Waddell N, 2008. Microarray-based DNA profiling to study genomic aberrations. IUBMB Life 60:437-440
10. Chen X, Jorgenson E, and Cheung ST, 2009. New tools for functional genomic analysis. Drug Discov Today 14:754-60
11. Ioerger TR and Sacchettini JC, 2009. Structural genomics approach to drug discovery for Mycobacterium tuberculosis. Curr Opin Microbiol 12:318-25
12. Plump AS and Lum PY, 2009. Genomics and cardiovascular drug development. J Am Coll Cardiol 53:1089-1100
13. de Vries B, Frants RR, Ferrari MD and van denMaagdenberg AM, 2009. Molecular genetics of migraine. Hum Genet 126:115-32
14. Gasser T, 2009. Molecular pathogenesis of Parkinson disease: Insights from genetic studies. Expert Rev Mol Med 11:e22
15. Kalman B and Vitale E, 2009. Structural chromosomal variations in neurological diseases. Neurologist 15:245-53
16. Latchman DS, 2007. Gene Regulation. New York: Taylor & Francis
17. Spannhoff A, Hauser AT, Heinke R et al., 2009. The emerging therapeutic potential of histone methyltransferase and demethylase inhibitors. ChemMedChem 4:1568-1582
18. Shukla A, Chaurasia P, Bhaumik SR, 2009. Histone methylation and ubiquitination with their cross-talk and roles in gene expression and stability. Cell Mol Life Sci 66:1419-1433.
19. Roeder RG, 1996. The role of general initiation factors in transcription by RNA polymerase II Trends Biochem Sci 21:327-335
20. Nikolov DB and Burley SK, 1997. RNA polymerase II transcription initiation: A structural view. Proc Natl Acad Sci USA 94:15-22
21. Lee TI and Young RA, 2000. Transcription of eukaryotic protein-coding genes. Annu Rev Genet 34:77-137
22. Xu EY, Schaefer WH, and Xu Q, 2009. Metabolomics in pharmaceutical research and development: Metabolites, mechanisms and pathways. Curr Opin Drug Discov Devel 12:40-52
23. Schiess R, Wollscheid B, and Aebersold R, 2009. Targeted proteomic strategy for clinical biomarker discovery. Mol Oncol 3:33-44
24. Lord PG, Nie A, and McMillianM, 2006. Application of genomics in preclinical drug safety evaluation. Basic Clin Pharmacol Toxicol 98:537-546
25. Waring JF and Halbert DN, 2002. The promise of toxicogenomics. Curr Opin Mol Ther 4:229-235
26. European Chemicals Agency, 2009. REACH and CLP guidance at http://guidance.echa.europa.eu/guidance_en.htm
27. European Chemicals Agency, 2009. at http://guidance.echa.europa.eu/index_en.htm
28. European Chemicals Agency, 2008. Guidance on information requirements and chemical safety assessment. Part B: Hazard assessment at http://guidance.echa.europa.eu/docs/guidance_document/information_requirements_part_b_en.pdf?vers=20_10_08